factual
England's NICE uses cost-effectiveness thresholds
England's NICE panel evaluates each treatment using a cost-effectiveness ratio of about £30,000 per life-year; drugs priced above that threshold are often repriced downward by manufacturers to qualify, and treatments deemed not sufficiently cost-effective are not paid for by the NHS, which is tremendously controversial when a drug just misses the threshold.
factualpending
Speaker
Jonathan SkinnerEvidence Quote
“if the treatment is not sufficiently cost-effective, they will often say, 'No, we're not going to provide this. We are not going to pay for this.'”
Created: 6/13/2026, 12:21:47 AM
Your notes
Loading notes...